Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cenya

Cenya SIGNED

Ex vivo cell labelling for in vivo imaging applied to cell therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cenya project word cloud

Explore the words cloud of the Cenya project. It provides you a very rough idea of what is the project "Cenya" about.

unbelievable    venture    track    market    push    advent    hired    300m    simpler    commercial    magic    size    repopulating    made    clinical    possess    opportunity    trials    checkpoint    exclusively    necessitating    drive    gmp    recruited    therapies    patients    fallen    lower    gene    stem    investment    ex    noninvasive    attractive    bedside    preclinical    40    vivo    validation    inhibitors    diseased    cell    techniques    ceo    decide    degree    staff    individual    monitor    deal    annum    nps    tissue    approval    surveyed    cancer    cells    safety    sometimes    data    curing    good    therapeutics    cenya    optimise    direct    car    cheaper    agents    trafficking    tracking    heart    lack    disease    play    seeing    nearly    faster    advisors    ready    medicine    nanoparticle    bench    industry    monitoring    modern    therapy    infusion    np    diagnose    biodistribution    treatments    hurdles    multiscale    imaging    transferred    day    outlined    regulatory    academics    expectations    suitable    labelling    licensing    optimisation    fda    labelled    time    while    lymphocyte   

Project "Cenya" data sheet

The following table provides information about the project.

Coordinator		 CENYA IMAGING B.V. 

Organization address
address: TWEEDE KOSTVERLORENKADE 11H
city: AMSTERDAM
postcode: 1052RK
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENYA IMAGING B.V. NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

While we do not possess magic, modern day medicine can sometimes approach the unbelievable - curing cancer or repopulating diseased heart tissue; all possible due to the advent of cell therapy. However, cell therapy has fallen far short of expectations. Its success requires the ability to monitor and optimise treatments in real time for each individual; necessitating a direct means of monitoring transferred cells. Noninvasive imaging techniques are essential to the success of modern therapeutics. Here, I will build on my work on developing multiscale GMP-ready imaging nanoparticle (NP) agents with the objective of out-licensing the technology to a new commercial venture, Cenya Imaging, to take this work from the bench to the bedside, and I have recruited an experienced CEO to drive this forward. Advisors have outlined a cheaper, faster and simpler path to regulatory approval for Cenya NPs: labelling cells ex vivo and tracking labelled cells after infusion into patients; since, with this approach, Cenya NPs are used to only track cells and not diagnose a disease, the regulatory hurdles are far lower. Recent developments in cell therapeutics have made tracking of cells a very attractive market; specifically (1) increasing investment in CAR-T cells, checkpoint inhibitors (which affect lymphocyte trafficking), and stem cell therapies (40% per annum growth in phase I trials); (2) regulatory push for increased safety and biodistribution data in trials; and (3) a lack of suitable clinical imaging agents. Market size is estimated at €300M; the FDA recently hired 50 new staff exclusively to deal with cell and gene therapies. We will exploit this new market, while also seeing this as the opportunity to play a significant role in the optimisation of cell therapies. We have surveyed nearly 100 users of cell therapy (preclinical, clinical; academics and industry) to decide on our approach, providing a good degree of validation for our choice of focus.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CENYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CENYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More